Zhang, Hanghang
Huang, Chen
Gordon, John
Yu, Sijia
Morton, George
Childers, Wayne
Abou-Gharbia, Magid
Zhang, Yi
Jelinek, Jaroslav
Issa, Jean-Pierre J.
Funding for this research was provided by:
National Institutes of Health (CA100632 and CA254897)
Article History
Received: 17 September 2023
Accepted: 15 December 2023
First Online: 3 January 2024
Declarations
:
: All animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Temple University.
: HZ, GM, WC, MAB, and JPJI are inventors in a patent covering chemical matter and usage of MC180295 and its enantiomers as anti-cancer agents. JPJI is a co-founder of EpiGenOnco, a company dedicated to the development of epigenetic therapies in cancer. EpiGenOnco has an option to license MC180295 from Temple University. HZ is a co-founder and shareholder of NexStage Bio, LLC (Malvern, PA), a company dedicated to developing methods to expand human cord blood hematopoietic stem cell (HSC) ex vivo to improve the success rate of bone marrow transplantation. HZ is also a co-founder and shareholder of EXIN BioPharm, Inc. (Montgomery, PA), a company dedicated to creating platforms to enhance protein expression and secretion.